Provider Education, Practice Champions Can Ensure Successful Integration of Biosimilars
Hundreds of millions of people worldwide rely on biologics to manage debilitating conditions and treat serious illnesses. These innovative therapies are particularly significant for patients with cancer, as they provide an alternative to hours of chemotherapy. As the patents of many biologics expire, opportunities to introduce biosimilar products are increasing. Biosimilars are biological products that have been shown to be highly similar to an already-approved biological product. The pre-approved agents are called reference products.
For the full article, check out Healio.